Moleculin Biotech, Inc. (MBRX) Operating income 2016–2025
Moleculin Biotech, Inc. (MBRX) annual operating income history from SEC filings — each fiscal year as reported.
-$25.1MFY2025 · since FY2016: -$3.9M → -$25.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$25.1M | +5.8% |
| FY2024 | -$26.6M | +10.1% |
| FY2023 | -$29.6M | +3.3% |
| FY2022 | -$30.6M | -33.4% |
| FY2021 | -$23.0M | -16.3% |
| FY2020 | -$19.7M | -12.7% |
| FY2019 | -$17.5M | -16.6% |
| FY2018 | -$15.0M | -73.6% |
| FY2017 | -$8.7M | -122.8% |
| FY2016 | -$3.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MBRX financial trends
MBRX RevenueMBRX Net incomeMBRX Net marginMBRX Gross profitMBRX Gross marginMBRX Operating marginMBRX Operating cash flowMBRX Free cash flowMBRX Capital expendituresMBRX Return on equityMBRX Stock buybacksMBRX Dividends paidMBRX Total assetsMBRX Total liabilitiesMBRX Shareholders’ equityMBRX overview →